MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Search

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

22.56 -0.09

Overview

Share price change

24h

Current

Min

22.05

Max

22.64

Key metrics

By Trading Economics

Income

202M

274M

Sales

5.4M

284M

P/E

Sector Avg

9.704

66.418

Profit margin

96.33

Employees

796

EBITDA

-21M

26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+41.53% upside

Dividends

By Dow Jones

Next Earnings

6 May 2026

Market Stats

By TradingEconomics

Market Cap

-378M

3.8B

Previous open

22.65

Previous close

22.56

Technical Score

By Trading Central

Confidence

Bullish Evidence

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Apr 2026, 18:16 UTC

Major News Events

Bank of Mexico Cautious After Interest-Rate Cut, Minutes Show

9 Apr 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 Apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 Apr 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 Apr 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9 Apr 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 Apr 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 Apr 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 Apr 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 Apr 2026, 20:57 UTC

Major News Events

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 Apr 2026, 20:55 UTC

Earnings

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 Apr 2026, 20:55 UTC

Earnings

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 Apr 2026, 20:55 UTC

Earnings

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 Apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 Apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Apr 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 Apr 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 Apr 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 Apr 2026, 20:25 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 Apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 Apr 2026, 19:30 UTC

Major News Events

How Digital Currencies Have Helped Iran -- WSJ

9 Apr 2026, 19:25 UTC

Market Talk

Crude Futures End Volatile Session Higher -- Market Talk

9 Apr 2026, 19:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 Apr 2026, 19:16 UTC

Market Talk

Livestock Mixed After USDA Cuts Production Outlook -- Market Talk

9 Apr 2026, 18:55 UTC

Market Talk

Global Energy Roundup: Market Talk

9 Apr 2026, 18:55 UTC

Market Talk

U.S. Natural Gas Futures Fall On Weather, Storage Data -- Market Talk

9 Apr 2026, 18:50 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 Apr 2026, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

9 Apr 2026, 18:44 UTC

Market Talk

Barrick's Former CEO Paid Severance Package of More Than $21 Million -- Market Talk

9 Apr 2026, 18:20 UTC

Market Talk
Major News Events

Oil Pulls Back As Israel to Negotiate With Lebanon -- Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

41.53% upside

12 Months Forecast

Average 31.93 USD  41.53%

High 40 USD

Low 23 USD

Based on 15 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Neutral Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat